Immunotherapy and chemotherapy before surgery for stage II-III lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether giving a combination of two immunotherapy drugs (ivonescimab or penpulimab) with chemotherapy before surgery helps shrink tumors and improve outcomes for people with early-stage non-small cell lung cancer. The goal is to make surgery more effective and reduce the chance of cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have non-small cell lung cancer that is stage IIA to IIIB and can be removed completely with surgery.
- Your tumor must appear solid or partly solid on a CT scan (not just a ground-glass shadow).
- You should be in generally good health, with normal lung and heart function, and be able to perform light daily activities.
- No prior treatment for your lung cancer.
- If you have certain genetic markers (EGFR mutations or ALK translocations), you are not eligible.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a new drug called Ivonescimab can improve outcomes when given before surgery for non-small cell lung cancer. It may help shrink tumors and make them easier to remove.
This trial tests a combination of low-dose radiation, an immunotherapy drug called sintilimab, and standard chemotherapy before surgery for stage II–III non-small cell lung cancer (NSCLC). The goal is to see if this approach can shrink tumors and improve outcomes for patients who are candidates for surgery.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests a new immunotherapy drug called ivonescimab, given alone or with chemotherapy, before and after surgery for non-small cell lung cancer that can be removed. The goal is to see if this treatment can reduce the chance of cancer coming back and improve outcomes for patients.
This trial tests combining two immunotherapy drugs (anti-CTLA-4 antibody and sintilimab) with chemotherapy before surgery for stage II-III non-small cell lung cancer. The goal is to see if this approach helps shrink tumors and improve outcomes.
This trial tests whether giving a combination of two immunotherapy drugs with chemotherapy before surgery can help shrink stage III lung cancer and improve outcomes. It is for people whose cancer has spread to lymph nodes in the chest but can still be removed with surgery.
Hear when a new Neoadjuvant Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.